The Global AsthmaTherapeutics Market, by Drug Class(Corticosteroids, Beta2-Agonists (Long-acting and Short-acting), Leukotriene Inhibitors,Long-acting Muscarinic Antagonists (LAMA), Interleukin Antagonists,Anti-immunoglobulin E (IgE) Agents, Combination Products (Including Beta2Agonists/Corticosteroids, Beta2 Agonists/MuscarinicAntagonists/Corticosteroids, and Others), and Others), by Route ofAdministration (Oral, Inhalation, and Injection), by Distribution Channel(Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),was valued at US$ XX million in 2017, and is projected to exhibit a CAGR of1.9%, during the forecast period (2018 - 2026), as highlighted in a new reportpublished by Coherent Market Insights.
Inhaler is a medical device,which facilitates the delivery of drug into body through lungs. It is mainlyused in the treatment of respiratory diseases and disorders including asthmaand chronic obstructive pulmonary disease (COPD). Inhaler divided into twotypes such as metered-dose inhaler and dry powder inhaler. Metered-doseinhalers are also called as aerosol-based inhalers. Dry powder inhalers are analternative of metered-dose-inhalers.
Thus, increasing approval forinhalers by regulatory authorities is expected to drive the global asthmatherapeutics market growth. For instance, in January 2019, Teva PharmaceuticalsIndustries received U.S. Food and Drug Administration (USFDA) approval for itsnew (ProAir Digihaler) digital Inhaler. It is used for the improvement andtreatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). ProAirDigihaler is a first digital inhaler. It is multi-dose dry powder inhaler, whichdelivers 117 µg of Albuterol.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2698
Furthermore, increasing number ofclinical trials for treatment of asthma is expected to boost the global asthmatherapeutics market value. For instance, in May 2018, Montefiore Medical Centerinitiated clinical study to evaluate the performance of ‘Adapting and Expandingthe Algorithmic Software Tool (ASTHMAXcel App)’. This software teachesfundamental concept of asthma and its management. The study started in May2018, and it is expected to complete in April 2020.
Browse 23 Market Data Tables and19 Figures spread through 157 Pages and in-depth TOC on "AsthmaTherapeutics Market, by Drug Class(Corticosteroids, Beta2-Agonists (Long-Acting and Short-Acting), LeukotrieneInhibitors, Long-Acting Muscarinic Antagonists (LAMA), Interleukin Antagonists,Anti-Immunoglobulin E (IgE) Agents, Combination Products (Including Beta2Agonists/Corticosteroids, Beta2 Agonists/MuscarinicAntagonists/Corticosteroids, and Others), and Others), by Route ofAdministration (Oral, Inhalation, and Injection), and by Distribution Channel(Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -Global Forecast to 2026"
Key players in the market arefocused on launching new products for asthma treatment. For instance, in May2019, FindAir Company, launched its new Smart Inhaler Device FindAir One inEurope. It is used for treatment of asthma and chronic obstructive pulmonarydisease (COPD). Moreover, in January 2019, FindAir One received CE marking fordistribution in the Europe.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/asthma-therapeutics-market-2698
Moreover, consistent research anddevelopment activities are expected to drive the global asthma therapeuticsmarket growth. For instance, in March 2018, Interregional Public Organizationand Russian Respiratory Society initiated a clinical study to collect anonymouslong-term evidences of severe asthma patients in Russia. The study is expectedto complete in December 2022. Furthermore, in February 2019, University ofChicago initiated phase II clinical study on Azithromycin for treatment ofasthma. This study is expected to complete in February 2020.
Key Takeaways of the GlobalAsthma Therapeutics Market:
The global asthma therapeuticsmarket is expected to witness a CAGR of 1.9% during the forecast period(2018–2026), owing to increasing product launches for improvement ofrespiratory disease including asthma and chronic obstructive pulmonary disease(COPD)
Among the regions, North Americais expected hold largest market share in global asthma therapeutics market overthe forecast period, owing to rising prevalence of respiratory diseases in theU.S. For instance, according to Centers for Disease Control and Prevention(CDC), in 2016, around 24 million people, including over 6 million children,suffered from asthma in the U.S.
Major players operating in theglobal asthma therapeutics market GlaxoSmithKline Plc., Philips Healthcare,AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH,Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck& Co., Inc., and Roche Diagnostics
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2698
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
